Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1252W HIGH $2.58
Volume
690.43 K
Value Traded
1.04 M
Short % Float
1.89%
-7.87%Week
-77.59%1 Month
-77.23%3 Month
-90.23%6 Month
-91.91%5 Year
-92.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.89 M
EPS (TTM)
-1.22
P/E Ratio
-
Ent. Value
44.82 M
Total Shares
22.21 M
Float Shares
21.80 M
Insiders
1.85%
Institutions
67.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ADGM Catalyst Timeline
Dated clinical, regulatory and corporate events for Adagio Medical Holdings, Inc
Past FDA Catalysts and PDUFA Decisions
How ADGM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Adagio Medical Holdings, Inc is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ADGM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Adagio's ULTC technology | ventricular tachycardia | Preclinical | 2026-02-05 | In a study of 20 patients with drug-refractory scar-related ventricular tachycardia, 92.9% achieved non-inducibility of targeted clinical VT, 72% had antiarrhythmic drugs discontinued or reduced, and 83.3% were free from ICD shock at a mean follow-up of 24 weeks.Read More | New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular TachycardiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kaster DeborahOfficer (Chief Financial Officer) | Grant/Award | 490,500 490,500 held | $0.00 | 03/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ADGM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.1 % | 6.44 M | 9.88 M | 161.23% ( 6.10 M) |
ADGM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ADGM ranks across every disease it competes in
Competitive Position is a premium feature
See how ADGM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialADGM News
ADGM▼ -53%on this news· ran to -65% by day 3
Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value
Adagio Medical Holdings, Inc. has announced the initiation of a strategic review process aimed at maximizing shareholder value. The Board of Directors completed a thorough evaluation of the company's business and resources, leading to this decision. This proactive step reflects the company's commitment to enhancing its market position.
Read more →ADGM▲ +8%on this news
Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix
Adagio Medical Holdings, Inc. has announced the successful treatment of the first patient in its IDE study for the vCLAS™ Ultra Ultra-Low Temperature Ablation System. This study aims to support a Premarket Approval supplement for the system, which targets ventricular tachycardia. The advancement highlights Adagio's commitment to innovating catheter ablation technologies.
Read more →ADGMAdagio Medical Reports Second Quarter 2026 Results
Adagio Medical Holdings, Inc. reported its financial results for the second quarter of 2026, highlighting a successful treatment of a patient using its next-generation vCLAS™ Ultra Ultra-Low temperature ablation catheter. This marks a significant advancement in their technology aimed at treating cardiac arrhythmias. The company continues to innovate in the field of catheter ablation.
Read more →ADGM▲ +21.6%on this news· ran to +111% by day 1
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
Adagio Medical Holdings, Inc. has successfully treated its first patient using the next-generation vCLAS Ultra ULTA system for cardiac arrhythmias. This treatment was conducted under Expanded Access authorization from the FDA, highlighting the system's potential in addressing non-ischemic cardiomyopathy. The advancement reflects Adagio's commitment to innovation in catheter ablation technologies.
Read more →ADGMAdagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Adagio Medical has submitted a Premarket Approval Application to the FDA for its vCLAS® Ventricular Ablation System. This system is designed to treat ventricular tachycardia, a serious heart condition. The submission marks a significant step in advancing treatment options for patients with this arrhythmia.
Read more →ADGMAdagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical has reported its financial results for the first quarter of 2026, highlighting significant clinical advancements. However, specific details regarding the clinical progress and financial metrics were not disclosed in the article. The report suggests a stable outlook for the company in the near term.
Read more →ADGMAdagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Adagio Medical Holdings, Inc. will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The company focuses on catheter ablation technologies for cardiac arrhythmias and is evaluating its vCLAS Ventricular Ablation System in the FULCRUM-VT U.S. Pivotal IDE Trial. This trial aims to support FDA premarket approval for the system.
Read more →ADGM▼ -23.8%on this news· ran to -40% by day 3shared move
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
Adagio Medical has announced positive pivotal results for its vCLAS® Ventricular Ablation System. The results indicate promising efficacy, which could lead to improved patient outcomes in the treatment of ventricular conditions. This development marks a significant step forward for the company's innovative technology in cardiac care.
Read more →ADGMAdagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Adagio Medical Holdings, Inc. will showcase its Ultra-low Temperature Ablation (ULTA) technologies at the Heart Rhythm 2026 conference in Chicago. The presentations will highlight the use of ULTA for treating scar-related ventricular tachycardia. The company is also conducting the FULCRUM-VT trial, which is pivotal for seeking FDA approval for its vCLAS™ Cryoablation System.
Read more →ADGM▲ +19.5%on this news
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
Adagio Medical has received Investigational Device Exemption (IDE) approval from the FDA for its next-generation vCLAS® Ventricular Ablation System. This approval allows the company to begin clinical investigations to evaluate the system's safety and effectiveness. The development marks a notable advancement in cardiac ablation technology.
Read more →ADGMAdagio Medical to Participate in the 25th Annual Needham Virtual Conference
Adagio Medical is set to participate in the 25th Annual Needham Virtual Conference. The event will provide a platform for the company to showcase its innovations and connect with investors. Further details about the conference and Adagio's presentation are currently limited.
Read more →ADGMAdagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
Adagio Medical Holdings, Inc. announced that pivotal results from the FULCRUM-VT study will be presented at the Heart Rhythm Society 2026 meeting. This study is the first IDE trial evaluating Ultra-Low Temperature Ablation for treating scar-related ventricular tachycardia. The presentation is scheduled for April 26, 2026, highlighting the significance of the findings for patient care.
Read more →ADGMAdagio Medical Reports Fourth Quarter and Full Year 2025 Results
Adagio Medical Holdings, Inc. reported its financial results for Q4 and full year 2025, highlighting significant milestones including the completion of patient enrollment in the FULCRUM-VT trial. The company noted a substantial reduction in net losses compared to 2024, attributed to decreased expenses and improved financial management. Adagio is focused on advancing its ULTA technology and preparing for commercialization of its vCLAS system.
Read more →ADGM▲ +11.5%on this newsshared move
Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
Adagio Medical has announced the publication of pre-clinical results for its next generation ventricular ablation catheter. The details of the results and their implications for future clinical applications were not disclosed in the announcement. This publication marks a significant step in the development of advanced cardiac treatment technologies.
Read more →ADGMAdagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference
Adagio Medical Holdings, Inc. will present at the TD Cowen 46th Annual Healthcare Conference on March 3, 2026. The company specializes in catheter ablation technologies for cardiac arrhythmias and is currently evaluating its vCLAS™ Cryoablation System in the FULCRUM-VT trial. This trial aims to support FDA premarket approval for the device.
Read more →ADGMNew Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia
Adagio Medical announced positive results from its Early Feasibility Study on ultralow temperature cardiac ablation for ventricular tachycardia. The study showed no major adverse events and a high success rate in preventing VT recurrence. The findings support the efficacy of Adagio's technology and highlight its potential for broader application in treating cardiac arrhythmias. The results will be pivotal for future regulatory approvals.
Read more →ADGMAdagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Adagio Medical Holdings, Inc. will participate in the BTIG 13th Annual MedTech Conference on February 10, 2026. The company focuses on catheter ablation technologies for cardiac arrhythmias, particularly with its vCLAS™ Cryoablation System. This system is currently under evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial, which aims for FDA premarket approval.
Read more →About Adagio Medical Holdings, Inc
Headquarters26051 MERIT CIRCLE, LAGUNA HILLS, CA, 92653
BIOPHARMAWATCH ELITE PLUS
Trade the next ADGM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime